Lincoln International’s Global Healthcare Group Announces Strong Results in 2022

Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance is especially notable given global healthcare M&A volumes saw a modest pull back in 2022 brought on by instability in the labor market, higher inflation and interest rates, pressure on reimbursements and the waning influence of COVID-19-era government-funded supports.

Despite these macro influences, we expect 2023 to be another active year for healthcare dealmaking as industry players and private equity utilize M&A as a strategy to keep pace with the ever-increasing complexities across healthcare access, quality and cost; regulatory pressures; reimbursement rates; software and technology integration; payment reforms and advances in pharma and medical technology.

Our team has deep domain expertise and transaction experience across a number of high growth areas of the global healthcare economy including:

  • Animal health
  • Behavioral and mental health
  • Fertility and women’s health
  • Healthcare IT and tech-enabled services
  • Home and community based care
  • Labs and lab services
  • Payor services and employer-funded insurance services
  • Pharma and medtech outsourcing
  • Physical / occupational / speech therapy and rehab
  • Physician services and ambulatory care
  • Value-based care enablement
  • Revenue cycle management


  • Lincoln International's Global Healthcare Group announces strong results in 2022.

Select Notable 2022 Healthcare Transactions

Related Perspectives

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More

Scrip Asks…What Does 2024 Hold for Biopharma?

James West, Managing Director in Lincoln’s Healthcare Group, recently discussed his expectations for the biopharma market in 2024 as part of Scrip’s series. Part One – Business Strategy and Leadership… Read More

2023 Global Results

Read More

Meet Our Senior Team in Healthcare